Evaxion Biotech A/S — Form 6-K Summary
Business Context and Reporting Period
Evaxion Biotech A/S, a Danish foreign private issuer, furnished this Form 6-K for February 2022. The filing reports a Share Sale and Restriction Agreement dated November 28, 2021, involving the company’s CEO, CFO and Chief Innovation Officer. The filing is incorporated by reference into the company’s Form S-8 registration statement No. 333-255064.
Key Financial and Capital-Market Information
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity or other operating financial metrics.
- CEO Lars Staal Wegner agreed to exercise 211,849 warrants, with exercise windows expected after publication of the annual report and interim reports in March, May, August and November 2022.
- Each warrant entitles the holder to subscribe for one ordinary share with a nominal value of DKK 1.
- For each exercise, Dr. Wegner agreed to sell the resulting ordinary shares during the corresponding trading window. CFO Niels Iversen Møller and Chief Innovation Officer Andreas Mattsson agreed to purchase the shares equally, at a price based on the Nasdaq-reported VWAP of the company’s ADSs on the exercise date.
- During each trading window, Dr. Møller and Mr. Mattsson were each required to sell 328,731 ADSs at the prevailing Nasdaq market price. The filing does not clearly state the aggregate number of ADSs represented by these sales.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative-period financial results. The material disclosed development is the agreement governing planned warrant exercises, transfers and sales of shares and ADSs by senior executives and co-founders.
Guidance, Outlook, Risks and Unusual Items
- Dr. Wegner agreed not to exercise additional warrants or sell additional ADSs or ordinary shares before December 31, 2022.
- The planned transactions are subject to the specified exercise and trading windows following publication of the company’s 2022 annual and interim financial reports.
- Dr. Møller and Mr. Mattsson were prohibited from exercising subsequent influence over how, when or whether their required sales would be executed.
- The transactions may affect the company’s share and ADS trading activity and ownership positions, but the filing provides no estimate of their market impact.
- No financial guidance or broader business outlook is provided.
Important Facts for Investors to Verify
- Confirm the number of warrants exercised and the shares issued in each scheduled exercise window.
- Verify the applicable VWAP and prevailing market prices used for the related transactions.
- Confirm the number of ADSs sold by each executive and the resulting ownership changes.
- Review subsequent Form 6-K filings and the 2022 annual and interim reports for completion or modification of the transactions.
- Review the referenced Form S-8 registration statement for the underlying warrant and share-registration details.